This company has been marked as potentially delisted and may not be actively trading. Obalon Therapeutics (OBLN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OBLN vs. NSPR, CTCX, TMDIF, HSAQ, PETV, GBS, RVP, BTCY, IVF, and DYNTShould you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include InspireMD (NSPR), Carmell (CTCX), Titan Medical (TMDIF), Health Sciences Acquisitions Co. 2 (HSAQ), PetVivo (PETV), GBS (GBS), Retractable Technologies (RVP), Biotricity (BTCY), INVO Fertility (IVF), and Dynatronics (DYNT). These companies are all part of the "medical" sector. Obalon Therapeutics vs. Its Competitors InspireMD Carmell Titan Medical Health Sciences Acquisitions Co. 2 PetVivo GBS Retractable Technologies Biotricity INVO Fertility Dynatronics InspireMD (NYSE:NSPR) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Is NSPR or OBLN more profitable? InspireMD has a net margin of -413.96% compared to Obalon Therapeutics' net margin of -776.76%. InspireMD's return on equity of -69.42% beat Obalon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets InspireMD-413.96% -69.42% -57.68% Obalon Therapeutics -776.76%-161.38%-83.58% Do analysts recommend NSPR or OBLN? InspireMD currently has a consensus price target of $4.50, suggesting a potential upside of 80.00%. Given InspireMD's stronger consensus rating and higher probable upside, analysts plainly believe InspireMD is more favorable than Obalon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InspireMD 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Obalon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, NSPR or OBLN? InspireMD has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Obalon Therapeutics has a beta of -1.23, suggesting that its stock price is 223% less volatile than the S&P 500. Which has stronger earnings & valuation, NSPR or OBLN? Obalon Therapeutics has lower revenue, but higher earnings than InspireMD. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInspireMD$7.07M14.76-$19.92M-$0.83-3.01Obalon Therapeutics$1.59M24.71-$12.33MN/AN/A Does the media prefer NSPR or OBLN? In the previous week, InspireMD had 1 more articles in the media than Obalon Therapeutics. MarketBeat recorded 1 mentions for InspireMD and 0 mentions for Obalon Therapeutics. InspireMD's average media sentiment score of 0.95 beat Obalon Therapeutics' score of 0.00 indicating that InspireMD is being referred to more favorably in the media. Company Overall Sentiment InspireMD Positive Obalon Therapeutics Neutral Do institutionals & insiders have more ownership in NSPR or OBLN? 44.8% of InspireMD shares are owned by institutional investors. Comparatively, 18.6% of Obalon Therapeutics shares are owned by institutional investors. 34.1% of InspireMD shares are owned by insiders. Comparatively, 8.1% of Obalon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryInspireMD beats Obalon Therapeutics on 12 of the 15 factors compared between the two stocks. Get Obalon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OBLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBLN vs. The Competition Export to ExcelMetricObalon TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.29M$75.26M$5.67B$9.83BDividend YieldN/AN/A3.79%4.08%P/E Ratio-2.9010.3230.5825.12Price / Sales24.7186.74464.55116.64Price / CashN/A18.4137.4059.05Price / Book6.537.429.096.18Net Income-$12.33M-$25.86M$3.25B$264.89M Obalon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBLNObalon TherapeuticsN/A$3.92+22.5%N/A+1,698.8%$39.29M$1.59M-2.902Gap DownNSPRInspireMD3.9959 of 5 stars$2.45-8.2%$4.50+83.7%-13.8%$75.06M$7.03M-3.2750Positive NewsGap UpCTCXCarmellN/A$2.84+0.4%N/A+140.0%$59.37M$32.84K0.0014TMDIFTitan MedicalN/A$0.33-7.1%N/A+895.7%$37.07M$17.63M-0.2650Gap DownHSAQHealth Sciences Acquisitions Co. 2N/A$2.68+9.8%N/A-52.0%$30.05MN/A0.004High Trading VolumePETVPetVivoN/A$0.84+4.5%N/A+39.5%$22.99M$1.05M-1.8620News CoverageGBSGBSN/A$1.47-7.0%N/A+33.6%$21.89MN/A-2.627RVPRetractable Technologies1.7384 of 5 stars$0.73flatN/A-26.2%$21.86M$33.75M-1.35240News CoverageShort Interest ↑BTCYBiotricityN/A$0.44+22.2%N/A+25.3%$10.96M$12.06M-0.4140News CoverageGap UpHigh Trading VolumeIVFINVO FertilityN/A$1.71-9.0%N/A-94.6%$1.23M$6.53M-0.0225News CoverageEarnings ReportGap DownHigh Trading VolumeDYNTDynatronicsN/A$0.08-0.5%N/A-47.1%$1.06M$33.60M-0.10200Gap Up Related Companies and Tools Related Companies NSPR Competitors CTCX Competitors TMDIF Competitors HSAQ Competitors PETV Competitors GBS Competitors RVP Competitors BTCY Competitors IVF Competitors DYNT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBLN) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Obalon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Obalon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access